Pleomorphic Liposarcoma Unraveled: Investigating Histopathological and Immunohistochemical Markers for Tailored Diagnosis and Therapeutic Innovations

被引:7
作者
Ciongariu, Ana-Maria [1 ,2 ]
Tapoi, Dana-Antonia [1 ,2 ]
Dumitru, Adrian-Vasile [1 ,2 ]
Bejenariu, Adrian [2 ]
Marin, Andrei [3 ]
Costache, Mariana [1 ,2 ]
机构
[1] Carol Davila Univ Med & Pharm, Dept Pathol, Bucharest 020021, Romania
[2] Univ Emergency Hosp, Dept Pathol, Bucharest 050098, Romania
[3] Carol Davila Univ Med & Pharm, Dept Plast Surg, Bucharest 020021, Romania
来源
MEDICINA-LITHUANIA | 2024年 / 60卷 / 06期
关键词
liposarcoma; pleomorphic liposarcoma; immunohistochemistry; TUMOR/WELL-DIFFERENTIATED LIPOSARCOMA; DEDIFFERENTIATED LIPOSARCOMA; MYXOID LIPOSARCOMA; SOFT-TISSUE; BREAST; MDM2; PULMONARY; OPTIONS; UTILITY;
D O I
10.3390/medicina60060950
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Liposarcomas are some of the most challenging soft tissue tumors and are subclassified into multiple subtypes with special histologic and molecular features. The peculiarities of each histopathological subtype influence the clinical behavior, management, and treatment of these neoplasms. For instance, well-differentiated liposarcomas are common soft tissue malignancies and usually display a favorable outcome. On the other hand, pleomorphic liposarcoma is the rarest, yet the most aggressive subtype of liposarcoma. This histopathological diagnosis may be challenging due to the scarce available data and because pleomorphic liposarcomas can mimic other pleomorphic sarcomas or other neoplasms of dissimilar differentiation. Nevertheless, the correct diagnosis of pleomorphic liposarcoma is of utmost importance as such patients are prone to develop local recurrences and metastases. Treatment usually consists of surgical excision along with radiotherapy and follow-up of the patients. Therefore, this review aims to assess the complex clinical, histological, and immunohistochemical features of liposarcomas in order to establish how these characteristics influence the management and prognosis of the patients, emphasizing the particularities of pleomorphic liposarcoma.
引用
收藏
页数:13
相关论文
共 84 条
[1]   A Case of GATA3 Positive Pleomorphic Liposarcoma, Epithelioid Variant: A Diagnostic Pitfall [J].
Abe, Makoto ;
Hoshi, Nobuo ;
Hoshi, Sayuri ;
Hirabayashi, Kaoru ;
Kikuta, Kazutaka ;
Hirozane, Toru ;
Nakagawa, Rumi ;
Mizuno, Tsukasa ;
Nakamura, Hiroshi ;
Inoue, Koichi ;
Yamaguchi, Takehiko .
CASE REPORTS IN PATHOLOGY, 2023, 2023
[2]   Pleomorphic liposarcoma of the head and neck: Presentation of two cases and literature review [J].
Agarwal, Jay ;
Kadakia, Sameep ;
Agaimy, Abbas ;
Ogadzanov, Anna ;
Khorsandi, Azita ;
Chai, Raymond L. .
AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2017, 38 (04) :505-507
[3]  
Al Kindi Adil H, 2023, Sultan Qaboos Univ Med J, V23, P271, DOI 10.18295/squmj.12.2022.064
[4]   Rare Pleomorphic Liposarcoma Presented as Jejunal Obstruction [J].
Al-Attar, Mohammad ;
Jnawali, Anup ;
Yang, Michelle .
CASE REPORTS IN PATHOLOGY, 2023, 2023
[5]   Pleomorphic liposarcoma: Updates and current differential diagnosis [J].
Anderson, William J. ;
Jo, Vickie Y. .
SEMINARS IN DIAGNOSTIC PATHOLOGY, 2019, 36 (02) :122-128
[6]   Multiply recurrent retroperitoneal liposarcoma [J].
Bagaria, Sanjay P. ;
Gabriel, Emmanuel ;
Mann, Gary N. .
JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (01) :62-68
[7]   Liposarcoma: molecular targets and therapeutic implications [J].
Bill, Kate Lynn J. ;
Casadei, Lucia ;
Prudner, Bethany C. ;
Iwenofu, Hans ;
Strohecker, Anne M. ;
Pollock, Raphael E. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2016, 73 (19) :3711-3718
[8]   Primary Breast Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma and Dedifferentiated Liposarcoma [J].
Briski, Laurence M. ;
Jorns, Julie M. .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2018, 142 (02) :268-274
[9]  
Burt Jeremy R, 2020, JACC Case Rep, V2, P1520, DOI 10.1016/j.jaccas.2020.05.099
[10]   Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma [J].
Chamberlain, Florence E. ;
Wilding, Chris ;
Jones, Robin L. ;
Huang, Paul .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (06) :505-511